Indivior is betting that more patients will switch to long‑lasting injectable treatment for opioid addiction, helped by easier use and a new awareness campaign that could keep people on therapy longer. The big question is whether cost cuts and a shift toward better‑paying customers can turn that momentum into stronger profits—or whether expectations are already too optimistic.Read more

US$50.83

20.4% undervalued

AnalystConsensusTarget's

Fair Value

Revenue

2.31% p.a.

Profit Margin

36.85%

Future PE

13.86x

Price in 2029

US$62.04

Indivior Pharmaceuticals

Long Acting Injectables And Cost Discipline Will Transform This Addiction Treatment Leader

Indivior is doubling down on its long-acting addiction shot, betting that easier dosing, wider insurance coverage, and a new awareness push can bring more people into treatment. At the same time, a hard cost-cutting plan could lift profits—but it risks slowing growth if the business gets too lean or if adoption doesn’t expand as hoped.Read more

US$58.33

30.7% undervalued

AnalystHighTarget's

Fair Value

Revenue

4.02% p.a.

Profit Margin

40.59%

Future PE

13.74x

Price in 2029

US$71.19

Trending Discussion

No trending discussion available.

Snowflake Analysis

Good value with slight risk.

4 Risks

4 Rewards

View Full Analysis

Indivior Pharmaceuticals, Inc. Key Details

Last Reported Earnings

Mar 31, 2026

Next Reporting Earnings

n/a

: 2.07
: 84.96%
: 19.53%
: -337.5%

View Full Analysis

About INDV

Founded: 2014
Employees: 833
CEO: Joseph Ciaffoni
WebsiteView website: www.indivior.com

Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company’s core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.